Triple Therapy for Atrial Fibrillation after PCI

Abstract

The management of atrial fibrillation in patients who have undergone percutaneous coronary intervention (PCI) for the treatment of coronary-artery disease is a common and difficult challenge. In patients with atrial fibrillation, oral anticoagulation is administered to reduce the risk of stroke. In patients who have undergone PCI, dual antiplatelet therapy is administered to prevent major adverse cardiovascular events and stent thrombosis. The use of triple therapy is common in clinical practice; one in four older patients with atrial fibrillation who have had an acute myocardial infarction receives triple therapy.¹ Although triple therapy may minimize the risk of stent thrombosis and . . .